Hepatocellular carcinoma with concomitant hepatic angiomyolipoma and cavernous hemangioma in one patient

Ge, Xiaowen; Zeng, Hai‐Ying; Sujie, Akesu; Du, Min; Ji, Yuan; Tan, Yun-Shan; Hou, Yingyong; Xu, Jianfang

doi:10.3748/wjg.v21.i11.3414

Cited by 8 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fast growth, high degrees of malignancy and metastasis, and high recurrence rate after surgical resection lead to poor outcomes for hepatocellular carcinoma (HCC) patients [ 1 ]. HCC morbidity and mortality rank 5 th and 3 rd , respectively, among malignant tumors worldwide, with an estimated 750,000 new cases and 700,000 deaths in 2008 [ 2 , 3 ]. HCC is triggered by inactivation of tumor suppressor genes and abnormal activation of proto-oncogenes in liver cells, aberrantly regulating several signaling pathways that form complex molecular regulatory networks through “cross talk” to promote tumorigenesis [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression

Wang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

This study aims to explore the effects of microRNA-126 (miR-126) on tumor proliferation and angiogenesis of hepatocellular carcinoma (HCC) by targeting EGFL7. HCC tissues and adjacent normal tissues were obtained from 71 HCC patients. Immunohistochemistry (IHC) was conducted to detect expressions of EGFL7 and VEGF and the micro-vessel density (MVD). HCC cell lines were collected and assigned into the blank, miR-126 mimics, miR-126 inhibitors, miR-126 mimics negative control (NC), miR-126 inhibitors NC, si-EGFL7, and miR-126 inhibitors + si-EGFL7 groups. Expressions of miR-126 and EGFL7 mRNA were detected by qRT-PCR assay. The protein expressions of EGFL7 and VEGF were measured by Western blotting. MTT assay was used to measure the proliferation of HCC cells. Tumor xenograft model in nude mice was utilized to evaluate the influence of miR-126 on tumor growth. HCC tissues had higher miR-126 expression and lower EGFL7 mRNA expression than adjacent normal tissues. Compared with the blank, miR-126 mimic NC, miR-126 inhibitor NC and miR-126 inhibitors + si-EGFL7 groups, the protein expressions of EGFL7 and VEGF and cell proliferation were reduced in the miR-126 mimics and si-EGFL7 groups, while the opposite trend was found in the miR-126 inhibitors group. Compared with the blank and miR-126 inhibitors + siRNA-EGFL7 groups, tumor size, tumor weight, and MVD of transplanted tumors in nude mice were significantly reduced in the miR-126 mimics and siRNA-EGFL7 groups, while the opposite trend was found in the miR-126 inhibitors group. In conclusion, miR-126 could inhibit tumor proliferation and angiogenesis of HCC by down-regulating EGFL7 expression.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression

Wang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…HCC is the most common malignant tumor of the liver and the 3 rd most common cause of cancer related mortality worldwide. The patient in this case was successfully treated with surgical resection of the tumor followed by one-month trans arterial chemoembolization (TACE) treatment; indeed, HCC needs to be removed surgically 29 .…”

Section: Everolimusmentioning

confidence: 99%

Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?

et al. 2016

View full text Add to dashboard Cite

Tuberous sclerosis complex (TSC) is an autosomal dominant and multi-system genetic disorder in humans. TSC affects around 25,000 to 40,000 individuals in the United States and about 1 to 2 million individuals worldwide, with an estimated prevalence of one in 6,000 newborns. TSC occurs in all races and ethnic groups, and in both genders. TSC is caused by defects or mutations in two genes, TSC1 and TSC2. Loss of TSC1/TSC2 leads to dysregulation of mTOR, resulting in aberrant cell differentiation and development, and abnormal enlargement of cells. TSC is characterized by the development of benign and/or malignant tumors in several organs including renal/liver angiomyolipomas, facial angiofibroma, lymphangiomyomatosis, cardiac rhabdomyomas, retinal astrocytic, renal cell carcinoma, and brain subependymal giant cell astrocytomas (SEGA). In addition, TSC disease causes disabling neurologic disorders, including epilepsy, mental retardation and autism. Particularly problematic are the development of renal angiomyolipomas, which tend to be larger, bilateral, multifocal and present at a younger age compared with sporadic forms. In addition, SEGA block the flow of fluid within the brain, causing a buildup of fluid and pressure that leads to blurred vision and seizures. In the current review, we describe the pathology of TSC disease in key organs and summarize the use of mTOR inhibitors to treat tumors in TSC patients.

show abstract

“…For a single hepatic angiomyolipoma > 5 cm in diameter, which cannot be con rmed by imaging and needle biopsy, surgical resection should be performed if there are no obvious surgical contraindications (11). However, for the treatment of rare tumors with relatively small diameters and scattered multiple tumors as in this patient, and a patient with multiple non-hepatitis B reported by Abbas Agaimy et al was followed up by puncture (13). Three patients with multiple non-hepatitis B reported by Yan Tan et al (14), Victor Chai et al (15), and Adam Durczyński et al(16), underwent segment resection (Table ).…”

Section: Discussionmentioning

confidence: 88%

A patient with hepatitis B virus infection had hepatic epithelioid angiomyolipoma scattered in the liver which was not suitable for surgical resection: A case report

Cai

Sun²,

Deng

et al. 2022

Preprint

View full text Add to dashboard Cite

Hepatic epithelioid angiomyolipoma (HEAML) is a rare tumor of mesenchymal tissue with a malignant tendency. It most frequently occurs in women. According to incomplete statistics, the incidence in men and women is approximately 1:5. Most HEAML lesions are single, and the lesions are generally located in the right lobe of the liver. In rare cases, the occurrence and development of the disease is hidden, the lesions are generally found by chance by patients, there are no special signs, and imaging has no specificity in the diagnosis of the disease. In addition, the misdiagnosis rate is very high with an accuracy rate of < 32%. Therefore, it has led to great difficulties in our diagnosis and treatment. This patient was a middle-aged female with a history of hepatitis B and no other special symptoms. She is a patient with multiple intrahepatic angiomyolipoma. Due to the small and scattered foci, complete resection was impossible, and due to her history of hepatitis B, conservative treatment was taken, and regular follow-up was performed. There was no tumor neogenesis or metastasis at the one-year follow-up.

show abstract

Hepatocellular carcinoma with concomitant hepatic angiomyolipoma and cavernous hemangioma in one patient

Cited by 8 publications

References 24 publications

MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression

MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression

Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?

A patient with hepatitis B virus infection had hepatic epithelioid angiomyolipoma scattered in the liver which was not suitable for surgical resection: A case report

Contact Info

Product

Resources

About